These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 16935747)

  • 1. The virtual laboratory approach to pharmacokinetics: design principles and concepts.
    Huisinga W; Telgmann R; Wulkow M
    Drug Discov Today; 2006 Sep; 11(17-18):800-5. PubMed ID: 16935747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Application of full physiological models for pharmaceutical drug candidate selection and extrapolation of pharmacokinetics to man.
    Parrott N; Jones H; Paquereau N; Lavé T
    Basic Clin Pharmacol Toxicol; 2005 Mar; 96(3):193-9. PubMed ID: 15733214
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A4S: a user-friendly graphical tool for pharmacokinetic and pharmacodynamic (PK/PD) simulation.
    Germani M; Del Bene F; Rocchetti M; Van Der Graaf PH
    Comput Methods Programs Biomed; 2013 May; 110(2):203-14. PubMed ID: 23182621
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Study design and simulation approach.
    Läer S; Meibohm B
    Handb Exp Pharmacol; 2011; 205():125-48. PubMed ID: 21882109
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-linear mixed-effects pharmacokinetic/pharmacodynamic modelling in NLME using differential equations.
    Tornøe CW; Agersø H; Jonsson EN; Madsen H; Nielsen HA
    Comput Methods Programs Biomed; 2004 Oct; 76(1):31-40. PubMed ID: 15313540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modeling in translational drug research.
    Danhof M; de Lange EC; Della Pasqua OE; Ploeger BA; Voskuyl RA
    Trends Pharmacol Sci; 2008 Apr; 29(4):186-91. PubMed ID: 18353445
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reification of abstract concepts to improve comprehension using interactive virtual environments and a knowledge-based design: a renal physiology model.
    Alverson DC; Saiki SM; Caudell TP; Goldsmith T; Stevens S; Saland L; Colleran K; Brandt J; Danielson L; Cerilli L; Harris A; Gregory MC; Stewart R; Norenberg J; Shuster G; Panaoitis ; Holten J; Vergera VM; Sherstyuk A; Kihmm K; Lui J; Wang KL
    Stud Health Technol Inform; 2006; 119():13-8. PubMed ID: 16404004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Integration of in silico and in vitro platforms for pharmacokinetic-pharmacodynamic modeling.
    Sung JH; Esch MB; Shuler ML
    Expert Opin Drug Metab Toxicol; 2010 Sep; 6(9):1063-81. PubMed ID: 20540627
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Automated reporting of pharmacokinetic study results: gaining efficiency downstream from the laboratory.
    Schaefer P
    Bioanalysis; 2011 Jul; 3(13):1471-8. PubMed ID: 21728771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and application of physiologically based pharmacokinetic-modeling tools to support drug discovery.
    Lüpfert C; Reichel A
    Chem Biodivers; 2005 Nov; 2(11):1462-86. PubMed ID: 17191947
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interdependency of pharmacokinetic parameters: a chicken-and-egg problem? Not!
    Mehvar R
    J Pharm Pharm Sci; 2006; 9(1):113-8. PubMed ID: 16849012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In silico toxicology for the pharmaceutical sciences.
    Valerio LG
    Toxicol Appl Pharmacol; 2009 Dec; 241(3):356-70. PubMed ID: 19716836
    [TBL] [Abstract][Full Text] [Related]  

  • 13. sigTOOL: A MATLAB-based environment for sharing laboratory-developed software to analyze biological signals.
    Lidierth M
    J Neurosci Methods; 2009 Mar; 178(1):188-96. PubMed ID: 19056423
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reverse-engineering clinical biology. A peacetime dividend yields drug trials on virtual patients.
    Stix G
    Sci Am; 2003 Feb; 288(2):18-9. PubMed ID: 12561454
    [No Abstract]   [Full Text] [Related]  

  • 15. PK/PD modelling and simulations: utility in drug development.
    Rajman I
    Drug Discov Today; 2008 Apr; 13(7-8):341-6. PubMed ID: 18405847
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New mathematical methods in pharmacokinetic modeling.
    Durisová M; Dedík L
    Basic Clin Pharmacol Toxicol; 2005 May; 96(5):335-42. PubMed ID: 15853925
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Simulation of complex pharmacokinetic models in Microsoft Excel.
    Meineke I; Brockmöller J
    Comput Methods Programs Biomed; 2007 Dec; 88(3):239-45. PubMed ID: 17981357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Critique of Computer Simulation Software's Used in Pharmacokinetics and Pharmacodynamics Analysis.
    Dave V; Yadav RB; Yadav S; Sharma S; Sahu RK; Ajayi AF
    Curr Clin Pharmacol; 2018; 13(4):216-235. PubMed ID: 30360723
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent advances in pharmacokinetic modeling.
    Ahmad AM
    Biopharm Drug Dispos; 2007 Apr; 28(3):135-43. PubMed ID: 17295411
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Methods for simulating the dynamics of complex biological processes.
    Schilstra MJ; Martin SR; Keating SM
    Methods Cell Biol; 2008; 84():807-42. PubMed ID: 17964950
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.